Incidence of Hepatitis B and HIV Virus at Cadaver of IV Drug Abusers in Tehran
-
Hassan Tofigi
,
Mazaher Ghorbani
,
Mitra Akhlaghi
,
Asadollah Yaghmaei
,
Babak Mostafazadeh
,
Esmaeel Farzaneh
,
Ali Reza Mohaghegh
Abstract
Injection drug use has been the most growing rout of drug abuse in Iran in the past decade and it has been responsible for the transmission of HIV virus in more than two third of cases. The aim of the present study was to determine the prevalence of HIV and hepatitis B in a group of IDU cadavers and to compare the results to a group of cadavers of the normal population. In a case-control study the blood samples of the cadavers of 400 randomly chosen IDUS and 400 other cadavers as control group were checked for HBS antigen and Anti HIV antibody in the forensic medicine center of Tehran. The prevalence of HIV and HBV infection was compared in two groups according to their demographic characteristics. The number of HIV and HBV positive cadavers was significantly higher in the IDU group than the controls (6.25% vs 0.5%, P<0.001, 27.5% vs 3%, P<0.001). The risk of getting infected by HIV virus was 13.27 times greater in the IDU group and the risk of HBV infection was 12.26 times greater in this group as compared to the control group. The age distribution of IDU cadavers indicated that the percentage of IDU cadavers in the reproductive (21-40 years old) age was 80%. The greater prevalence of the HIV and HBV infection especially in the reproductive age of IDUS indicates a greater concern to the authorities for more attention to prevention and harm reduction programs.
United Nations Office on Drugs and Crime (UNODC). World Drug Report [Online]. 2005 [cited 2011 Mar 1]; Vienna: United Nations Office on Drugs and Crime; Available from: URL:http://www.unodc.org/pdf/WDR_2005/volume_1_we b.pdf
The Guardian: World News. Iran faces up to its most lethal threat-drugs [Online]. 2005 [cited 2001 Mar 1]. Available from:URL:http://www.guardian.co.uk/world/2005/oct/27/iran.roberttait
Razzaghi EM, Rahimi Movaghar A, Hosseini M, Madani S, Chatterjee A. Rapid Situation Assessment of Drug Abuse in Iran. Iranian Welfare Organization and UNDCP, 1999.
Iran News Daily. 300000 intravenous drug users in Iran. Editorial 2001. OpenURL. June 26, 2001.
Wodak A: Report to WHO/EMRO regarding control of HIV among and from injecting drug users in the IR Iran. 1997. Unpublished.
MAP Network (Monitoring the AIDS pandemic): The Status and Trendsd of HIV/AIDS/STI Epidemics in Asia and the Pacific. MAP Provisional Report [Online]. 2001 [cited Mar 1]; Available from:URL:http://pdf.usaid.gov/pdf_docs/PNACM798.pdf
WHO Library Catologuing-in-Publication Data UNAIDS anniversary special edition [Online]. 2006 Dec [cited 2011 Mar 1]; Available from: URL:data.unaids.org/pub/GlobalReport/2006/2006_grexecutivesummary_en.pdf
Rahbar RA, Rooholamini S, Khoshnood K: Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUS) in Mashhad, Iran. Int J Drug Policy 2004;15:151-5.
Iranian Ministry of Health and Medical Education: Statistics on HIV/AIDS in Iran, 2003.
Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Singer M, Stopka T, Siano C, Springer K, Barton G, Khoshnood K, Garry de Puga, Heimer R. The social geography of AIDS and hepatitis risk: qualitative approaches for assessing local differences in sterile-syringe access among injection drug users. Am J Public Health 2000;90(7):1049-56.
Schleicher S, Schieffer M, Jürgens S, Wehner HD, Flehmig B. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts. Ig Sanita Pubbl 2005;61(5):435-50.
Wiessing L, Nardone A. Ongoing HIV and viral hepatitis infections in IDUs across the EU, 2001-2005. Euro Surveill 2006;11(11):E061123.2.
Vassilev ZP, Hagan H, Lyubenova A, Tomov N, Vasilev G, Krasteva D, Des Jarlais DC. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users. Int J STD AIDS 2006;17(9):621-6.
Fisher DG, Reynolds GL, Jaffe A, Perez MJ. Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J Addict Dis 2006;25(2):25-32.
Gyarmathy VA, Neaigus A, Ujhelyi E, Szabó T, Rácz J. Strong HIV and hepatitis disclosure norms and frequent risk behaviors among Hungarian drug injectors. Drug Alcohol Depend 2006;82 Suppl 1:S65-9.
Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviors and HIV, hepatitis B, and hepatitis Cseroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006;82 Suppl 1:S35-8.
Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000;18(3):145-50.
Crofts N, Hopper JL, Milner R, Breschkin AM, Bowden DS, Locarnini SA. Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV. Eur J Epidemiol 1994;10(6):687-94.
Santolamazza M, Delle Monache M, Alvino A, Bacosi M, D'Innocenzo S, Ciervo U, Antonaci A, Russo F, Miglioresi L, De Angelis A, Ursitti A, Ricci GL. Multiple viral infections in a group of intravenous drug users: hepatitis B virus exposure is the risk factor. Eur J Gastroenterol Hepatol 2001;13(11):1347-54.
Devi KhS, Brajachand N, Singh HL, Singh YM. Coinfection by human immunodeficiency virus, hepatitis B and hepatitis C virus in injecting drug users. J Commun Dis 2005;37(1):73-7.
| Files | ||
| Issue | Vol 49, No 1 (2011) | |
| Section | Original Article(s) | |
| Keywords | ||
| Drug user Cadaver Hepatitis B HIV infections | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
